Abstract
We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
Keywords:
Acute myeloid leukemia; Antibody-drug conjugate; CD33.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antineoplastic Agents, Immunological / administration & dosage*
-
Female
-
Genotype
-
Humans
-
Immunoconjugates / administration & dosage
-
Immunoconjugates / immunology
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics*
-
Leukemia, Myeloid, Acute / immunology
-
Male
-
Middle Aged
-
Polymorphism, Single Nucleotide
-
RNA Splicing
-
Sialic Acid Binding Ig-like Lectin 3 / genetics*
-
Sialic Acid Binding Ig-like Lectin 3 / immunology*
-
Survival Rate
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
CD33 protein, human
-
Immunoconjugates
-
Sialic Acid Binding Ig-like Lectin 3
-
lintuzumab